Insider Selling: Trevi Therapeutics (NASDAQ:TRVI) Director Sells 39,473 Shares of Stock

Key Points

• Director Michael Thomas Heffernan sold 39,473 Trevi Therapeutics shares at an average price of $15.09, generating approximately $595,648. The transaction reduced his holdings by 86.14%, leaving him with 6,351 shares.
• Trevi shares recently traded at $15.23, up 1.5%, with a market capitalization of about $2.17 billion. The company reported quarterly EPS of -$0.11, in line with analyst expectations.
• Analysts maintain a consensus “Buy” rating with an average price target of $27.08, although some firms have issued “Sell” or downgraded ratings. Institutional investors own approximately 95.76% of the stock.

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Get Free Report) Director Michael Thomas Heffernan sold 39,473 shares of the business's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total value of $595,647.57. Following the completion of the transaction, the director owned 6,351 shares in the company, valued at $95,836.59. The trade was a 86.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Trevi Therapeutics Trading Up 1.5%

Shares of TRVI stock traded up $0.22 during trading on Thursday, hitting $15.23. The company's stock had a trading volume of 1,498,737 shares, compared to its average volume of 1,702,766. The company has a market cap of $2.17 billion, a PE ratio of -44.79 and a beta of 1.04. The business has a fifty day moving average of $17.60 and a 200-day moving average of $15.30. Trevi Therapeutics, Inc. has a 52 week low of $8.03 and a 52 week high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, hitting analysts' consensus estimates of ($0.11). As a group, research analysts predict that Trevi Therapeutics, Inc. will post -0.48 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. B. Riley Financial increased their price target on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a "buy" rating in a research report on Monday, July 20th. Wall Street Zen downgraded shares of Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. BMO Capital Markets assumed coverage on shares of Trevi Therapeutics in a research note on Monday, July 20th. They set an "outperform" rating and a $36.00 price target for the company. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $40.00 price target on shares of Trevi Therapeutics in a report on Friday, August 7th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Trevi Therapeutics in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $27.08.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Trevi Therapeutics during the first quarter worth about $29,000. Hilton Head Capital Partners LLC purchased a new stake in shares of Trevi Therapeutics during the 4th quarter valued at approximately $40,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Trevi Therapeutics during the 4th quarter valued at approximately $50,000. Avidity Partners Management LP purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at approximately $79,000. Finally, Seven Fleet Capital Management LP bought a new position in Trevi Therapeutics in the 4th quarter worth approximately $89,000. 95.76% of the stock is currently owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for chronic cough and other conditions involving dysregulated sensory nerve activity. The company's lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine designed to reduce chronic cough through activity at opioid receptors.

Trevi is studying Haduvio for chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, as well as refractory chronic cough, a condition in which coughing persists despite treatment of underlying causes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.